K63-linked ubiquitination in kinase activation and cancer

Frontiers in Oncology

Volumn 2, Issue JAN, 2012, Pages

  Wang, Guocan ^a   Gao, Yuan ^a,b   Li, Liren ^a   Jin, Guoxiang ^a,b   Cai, Zhen ^a,b   Chao, Jui I ^a,c   Lin, Hui Kuan ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Akt; NF B; Phosphorylation; Protein kinase; TRAF6; Tumorigenesis; Ubiquitination

Indexed keywords

CYCLIN D1; GROWTH FACTOR RECEPTOR; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

DOWN REGULATION; HUMAN; INFLAMMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION;

EID: 84878972377     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00005     Document Type: Review

References (171)

1. Adams, J., and Kauffman, M. (2004). Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304-311.
2. Adhikari, A., and Chen, Z. J. (2009). Diversity of polyubiquitin chains. Dev. Cell 16, 485-486.
3. Adhikary, S., and Eilers, M. (2005). Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6, 635-645.
4. Adhikary, S., Marinoni, F., Hock, A., Hulleman, E., Popov, N., Beier, R., Bernard, S., Quarto, M., Capra, M., Goettig, S., Kogel, U., Scheffner, M., Helin, K., and Eilers, M. (2005). The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123, 409-421.
5. Ahmed, N., Zeng, M., Sinha, I., Polin, L., Wei, W. Z., Rathinam, C., Flavell, R., Massoumi, R., and Venuprasad, K. (2011). The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 12, 1176-1183.
6. Askham, J. M., Platt, F., Chambers, P. A., Snowden, H., Taylor, C. F., and Knowles, M. A. (2010). AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 29, 150-155.
7. Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S., Stokoe, D., McCormick, F., Feng, J., and Tsichlis, P. (1998). Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17, 313-325.
8. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti Panici, P., Mancuso, S., Neri, G., and Testa, J. R. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280-285.
9. Bertrand, M. J., Lippens, S., Staes, A., Gilbert, B., Roelandt, R., De Medts, J., Gevaert, K., Declercq, W., and Vandenabeele, P. (2011). cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS ONE 6, e22356. doi:10.1371/journal.pone.0022356
10. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008). cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700.
11. Bhoj, V. G., and Chen, Z. J. (2009). Ubiquitylation in innate and adaptive immunity. Nature 458, 430-437.
12. Bignell, G. R., Warren, W., Seal, S., Takahashi, M., Rapley, E., Barfoot, R., Green, H., Brown, C., Biggs, P. J., Lakhani, S. R., Jones, C., Hansen, J., Blair, E., Hofmann, B., Siebert, R., Turner, G., Evans, D. G., Schrander-Stumpel, C., Beemer, F. A., van Den Ouweland, A., Halley, D., Delpech, B., Cleveland, M. G., Leigh, I., Leisti, J., and Rasmussen, S. (2000). Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25, 160-165.
13. Bold, R. (2004). Development of the proteasome inhibitor Velcade (Bortezomib) by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D. Cancer Invest. 22, 328-329.
14. Bosanac, I., Wertz, I. E., Pan, B., Yu, C., Kusam, S., Lam, C., Phu, L., Phung, Q., Maurer, B., Arnott, D., Kirkpatrick, D. S., Dixit, V. M., and Hymowitz, S. G. (2010). Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol. Cell 40, 548-557.
15. Brazil, D. P., Park, J., and Hemmings, B. A. (2002). PKB binding proteins. Getting in on the Akt. Cell 111, 293-303.
16. Bremm, A., Freund, S. M., and Komander, D. (2010). Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat. Struct. Mol. Biol. 17, 939-947.
17. Brummelkamp, T. R., Nijman, S. M., Dirac, A. M., and Bernards, R. (2003). Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424, 797-801.
18. Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
19. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., Uhlik, M., Lin, A., Du, J., Qian, Y. W., Zeckner, D. J., Tucker-Kellogg, G., Touchman, J., Patel, K., Mousses, S., Bittner, M., Schevitz, R., Lai, M. H., Blanchard, K. L., and Thomas, J. E. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-444.
20. Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., Yang, S. N., Garcia, M., Coop, A., Mackerell, A. D. Jr., Privé, G. G., and Melnick, A. (2010). A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17, 400-411.
21. Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., and Gu, W. (2005). ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121, 1071-1083.
22. Chen, M. L., Xu, P. Z., Peng, X. D., Chen, W. S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P. P., and Hay, N. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/-mice. Genes Dev. 20, 1569-1574.
23. Chen, W., White, M. A., and Cobb, M. H. (2002). Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway. J. Biol. Chem. 277, 49105-49110.
24. Chen, Z. J. (2005). Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7, 758-765.
25. Chen, Z. J., and Sun, L. J. (2009). Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275-286.
26. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. (1992). AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. U.S.A. 89, 9267-9271.
27. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., and Testa, J. R. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U.S.A. 93, 3636-3641.
28. Cohen, P., and Tcherpakov, M. (2010). Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143, 686-693.
29. Cohn, M. A., Kowal, P., Yang, K., Haas, W., Huang, T. T., Gygi, S. P., and D'Andrea, A. D. (2007). A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell. 28, 786-797.
30. Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Aushev, V. N., Camonis, J., Calabrese, A., Borg-Capra, C., Sippl, W., Collura, V., Boissy, G., Rain, J. C., Guedat, P., Delansorne, R., and Daviet, L. (2009). Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8, 2286-2295.
31. Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., Bhagat, G., Chadburn, A., Dalla-Favera, R., and Pasqualucci, L. (2009). Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717-721.
32. Conze, D. B., Wu, C. J., Thomas, J. A., Landstrom, A., and Ashwell, J. D. (2008). Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor-and toll-like receptor-mediated NF-kappaB activation. Mol. Cell. Biol. 28, 3538-3547.
33. Cooper, E. M., Cutcliffe, C., Kristiansen, T. Z., Pandey, A., Pickart, C. M., and Cohen, R. E. (2009). K63-specific deubiquitination by two JAMM/MPN+ complexes: BRISC-associated Brcc36 and proteasomal Poh1. EMBO J. 28, 621-631.
34. D'Arcy, P., Brnjic, S., Olofsson, M. H., Fryknäs, M., Lindsten, K., De Cesare, M., Perego, P., Sadeghi, B., Hassan, M., Larsson, R., and Linder, S. (2011). Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 17, 1636-1640.
35. Datta, S. R., Brunet, A., and Greenberg, M. E. (1999). Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927.
36. de Bie, P., and Ciechanover, A. (2011). Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ. 18, 1393-1402.
37. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P. P. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27, 222-224.
38. Dickey, C. A., Koren, J., Zhang, Y. J., Xu, Y. F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., Bailey, R. M., Dunmore, J., Soresh, S., Leon, C., Morgan, D., and Petrucelli, L. (2008). Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. U.S.A. 105, 3622-3627.
39. Ea, C. K., Deng, L., Xia, Z. P., Pineda, G., and Chen, Z. J. (2006). Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22, 245-257.
40. Enesa, K., Zakkar, M., Chaudhury, H., Luong le, A., Rawlinson, L., Mason, J. C., Haskard, D. O., Dean, J. L., and Evans, P. C. (2008). NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J. Biol. Chem. 283, 7036-7045.
41. Ermolaeva, M. A., Michallet, M. C., Papadopoulou, N., Utermöhlen, O., Kranidioti, K., Kollias, G., Tschopp, J., and Pasparakis, M. (2008). Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 9, 1037-1046.
42. Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q., Sessa, W. C., Qin, J., Zhang, P., Su, B., and Jacinto, E. (2008). The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27, 1932-1943.
43. Fraile, J. M., Quesada, V., Rodríguez, D., Freije, J. M., and López-Otín, C. (2011). Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. doi: 10.1038/onc.2011.443. [Epub ahead of print].
44. Gao, Z., Xu, M. S., Barnett, T. L., and Xu, C. W. (2011). Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells. Biochem. Biophys. Res. Commun. 407, 271-276.
45. Giasson, B. I., and Lee, V. M. (2003). Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8.
46. Gonzalez, E., and McGraw, T. E. (2009). The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8, 2502-2508.
47. Grech, A. P., Amesbury, M., Chan, T., Gardam, S., Basten, A., and Brink, R. (2004). TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 21, 629-642.
48. Ha, H., Han, D., and Choi, Y. (2009). TRAF-mediated TNFR-family signaling. Curr. Protoc. Immunol. Chapter 11, Unit11 19D.
49. Hasegawa, M., Fujimoto, Y., Lucas, P. C., Nakano, H., Fukase, K., Núñez, G., and Inohara, N. (2008). A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 27, 373-383.
50. Hasskarl, J., and Munger, K. (2002). Id proteins-tumor markers or oncogenes? Cancer Biol. Ther. 1, 91-96.
51. He, K. L., and Ting, A. T. (2002). A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol. Cell. Biol. 22, 6034-6045.
52. Heemers, H. V., and Tindall, D. J. (2009). Unraveling the complexities of androgen receptor signaling in prostate cancer cells. Cancer Cell 15, 245-247.
53. Heldin, C. H., Landstrom, M., and Moustakas, A. (2009). Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 21, 166-176.
54. Herold, S., Herkert, B., and Eilers, M. (2009). Facilitating replication under stress: an oncogenic function of MYC? Nat. Rev. Cancer 9, 441-444.
55. Hinz, M., Stilmann, M., Arslan, S. ç., Khanna, K. K., Dittmar, G., and Scheidereit, C. (2010). A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol. Cell 40, 63-74.
56. Hoeller, D., and Dikic, I. (2009). Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444.
57. Hou, J., Wang, P., Lin, L., Liu, X., Ma, F., An, H., Wang, Z., and Cao, X. (2009). MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 183, 2150-2158.
58. Hu, M., Li, P., Song, L., Jeffrey, P. D., Chenova, T. A., Wilkinson, K. D., Cohen, R. E., and Shi, Y. (2005). Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 24, 3747-3756.
59. Huen, M. S., Grant, R., Manke, I., Minn, K., Yu, X., Yaffe, M. B., and Chen, J. (2007). RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131, 901-914.
60. Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., and Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 69, 1279-1283.
61. Hymowitz, S. G., and Wertz, I. E. (2010). A20: from ubiquitin editing to tumour suppression. Nat. Rev. Cancer 10, 332-341.
62. Hynes, N. E., and MacDonald, G. (2009). ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177-184.
63. Inohara, N., Koseki, T., Lin, J., del Peso, L., Lucas, P. C., Chen, F. F., Ogura, Y., and Núñez, G. (2000). An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 275, 27823-27831.
64. Kanayama, A., Seth, R. B., Sun, L., Ea, C. K., Hong, M., Shaito, A., Chiu, Y. H., Deng, L., and Chen, Z. J. (2004). TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 15, 535-548.
65. Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., Niwa, A., Chen, Y., Nakazaki, K., Nomoto, J., Asakura, Y., Muto, S., Tamura, A., Iio, M., Akatsuka, Y., Hayashi, Y., Mori, H., Igarashi, T., Kurokawa, M., Chiba, S., Mori, S., Ishikawa, Y., Okamoto, K., Tobinai, K., Nakagama, H., Nakahata, T., Yoshino, T., Kobayashi, Y., and Ogawa, S. (2009). Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712-716.
66. Kim, M. S., Jeong, E. G., Yoo, N. J., and Lee, S. H. (2008a). Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98, 1533-1535.
67. Kim, P. K., Hailey, D. W., Mullen, R. T., and Lippincott-Schwartz, J. (2008b). Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc. Natl. Acad. Sci. U.S.A. 105, 20567-20574.
68. Kirkin, V., McEwan, D. G., Novak, I., and Dikic, I. (2009). A role for ubiquitin in selective autophagy. Mol. Cell 34, 259-269.
69. Klein, S., and Levitzki, A. (2009). Targeting the EGFR and the PKB pathway in cancer. Curr. Opin. Cell Biol. 21, 185-193.
70. Komander, D., Reyes-Turcu, F., Licchesi, J. D., Odenwaelder, P., Wilkinson, K. D., and Barford, D. (2009). Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466-473.
71. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israël, A., Wallach, D., and Courtois, G. (2003). The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801-805.
72. Kraft, C., Peter, M., and Hofmann, K. (2010). Selective autophagy: ubiquitin-mediated recognition and beyond. Nat. Cell Biol. 12, 836-841.
73. Kulathu, Y., Akutsu, M., Bremm, A., Hofmann, K., and Komander, D. (2009). Two-sided ubiquitin binding explains specificity of the TAB2 NZF domain. Nat. Struct. Mol. Biol. 16, 1328-1330.
74. Lee, K. Y., Yang, K., Cohn, M. A., Sikdar, N., D'Andrea, A. D., and Myung, K. (2010). Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through Its interactions with PCNA and USP1. J. Biol. Chem. 285, 10362-10369.
75. Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K. III, Siegel, P. M., Hung, M. C., Yarden, Y., Horowitz, J. M., Muller, W. J., and Pestell, R. G. (2000). Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20, 672-683.
76. Li, L., Soetandyo, N., Wang, Q., and Ye, Y. (2009). The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793, 346-353.
77. Li, Z., Wang, D., Messing, E. M., and Wu, G. (2005). VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 6, 373-378.
78. Liang, J., Saad, Y., Lei, T., Wang, J., Qi, D., Yang, Q., Kolattukudy, P. E., and Fu, M. (2010). MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J. Exp. Med. 207, 2959-2973.
79. Lim, K. L., and Lim, G. G. (2011). K63-linked ubiquitination and neurodegeneration. Neurobiol. Dis. 43, 9-16.
80. Liu, H. H., Xie, M., Schneider, M. D., and Chen, Z. J. (2006). Essential role of TAK1 in thymocyte development and activation. Proc. Natl. Acad. Sci. U.S.A. 103, 11677-11682.
81. Luise, C., Capra, M., Donzelli, M., Mazzarol, G., Jodice, M. G., Nuciforo, P., Viale, G., Di Fiore, P. P., and Confalonieri, S. (2011). An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 6, e15891.
82. Lynch, O. T., and Gadina, M. (2004). Ubiquitination for activation: new directions in the NF-kappaB roadmap. Mol. Interv. 4, 144-146.
83. Mailand, N., Bekker-Jensen, S., Faustrup, H., Melander, F., Bartek, J., Lukas, C., and Lukas, J. (2007). RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131, 887-900.
84. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., Loda, M., Lane, H. A., and Sellers, W. R. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601.
85. Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P. W., Golub, T. R., Loda, M., and Sellers, W. R. (2003). Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. U.S.A. 100, 7841-7846.
86. Malanga, D., Scrima, M., De Marco, C., Fabiani, F., De Rosa, N., De Gisi, S., Malara, N., Savino, R., Rocco, G., Chiappetta, G., Franco, R., Tirino, V., Pirozzi, G., and Viglietto, G. (2008). Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7, 665-669.
87. Martinez-Forero, I., Rouzaut, A., Palazon, A., Dubrot, J., and Melero, I. (2009). Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clin. Cancer Res. 15, 6751-6757.
88. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A., and Fässler, R. (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125, 665-677.
89. Mauro, C., Pacifico, F., Lavorgna, A., Mellone, S., Iannetti, A., Acquaviva, R., Formisano, S., Vito, P., and Leonardi, A. (2006). ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J. Biol. Chem. 281, 18482-18488.
90. McCullough, J., Clague, M. J., and Urbé S. (2004). AMSH is an endosome-associated ubiquitin isopeptidase. J. Cell Biol. 166, 487-492.
91. Metzig, M., Nickles, D., Falschlehner, C., Lehmann-Koch, J., Straub, B. K., Roth, W., and Boutros, M. (2011). An RNAi screen identifies USP2 as a factor required for TNF-alpha-induced NF-kappaB signaling. Int. J. Cancer 129, 607-618.
92. Mohamedali, A., Lea, N. C., Feakins, R. M., Raj, K., Mufti, G. J., and Kocher, H. M. (2008). AKT1 (E17K) mutation in pancreatic cancer. Technol. Cancer Res. Treat. 7, 407-408.
93. Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., and Sutherland, R. L. (2011). Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558-572.
94. Nakada, S., Tai, I., Panier, S., Al-Hakim, A., Iemura, S., Juang, Y. C., O'Donnell, L., Kumakubo, A., Munro, M., Sicheri, F., Gingras, A. C., Natsume, T., Suda, T., and Durocher, D. (2010). Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 466, 941-946.
95. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., and Roth, R. A. (1999). Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 274, 21528-21532.
96. Nicassio, F., Corrado, N., Vissers, J. H., Areces, L. B., Bergink, S., Marteijn, J. A., Geverts, B., Houtsmuller, A. B., Vermeulen, W., Di Fiore, P. P., and Citterio, E. (2007). Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr. Biol. 17, 1972-1977.
97. Ninomiya-Tsuji, J., Kajino, T., Ono, K., Ohtomo, T., Matsumoto, M., Shiina, M., Mihara, M., Tsuchiya, M., and Matsumoto, K. (2003). A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 278, 18485-18490.
98. Niu, J., Shi, Y., Iwai, K., and Wu, Z. H. (2011). LUBAC regulates NF-kappaB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J. 30, 3741-3753.
99. Novak, U., Rinaldi, A., Kwee, I., Nandula, S. V., Rancoita, P. M., Compagno, M., Cerri, M., Rossi, D., Murty, V. V., Zucca, E., Gaidano, G., Dalla-Favera, R., Pasqualucci, L., Bhagat, G., and Bertoni, F. (2009). The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113, 4918-4921.
100. Opferman, J. T., and Green, D. R. (2010). DUB-le trouble for cell survival. Cancer Cell 17, 117-119.
101. Ordureau, A., Smith, H., Windheim, M., Peggie, M., Carrick, E., Morrice, N., and Cohen, P. (2008). The IRAK-catalysed activation of the E3 ligase function of Pellino isoforms induces the Lys63-linked polyubiquitination of IRAK1. Biochem. J. 409, 43-52.
102. Park, J. H., Kim, Y. G., McDonald, C., Kanneganti, T. D., Hasegawa, M., Body-Malapel, M., Inohara, N., and Núñez, G. (2007). RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J. Immunol. 178, 2380-2386.
103. Pelengaris, S., Khan, M., and Evan, G. (2002). c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764-776.
104. Pereg, Y., Liu, B. Y., O'Rourke, K. M., Sagolla, M., Dey, A., Komuves, L., French, D. M., and Dixit, V. M. (2010). Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat. Cell Biol. 12, 400-406.
105. Perk, J., Iavarone, A., and Benezra, R. (2005). Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer 5, 603-614.
106. Pickart, C. M. (2001). Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533.
107. Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., Elledge, S. J., and Eilers, M. (2007). The ubiquitin-specific protease USP28 is required for MYC stability. Nat. Cell Biol. 9, 765-774.
108. Raiborg, C., and Stenmark, H. (2009). The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445-452.
109. Razani, B., Zarnegar, B., Ytterberg, A. J., Shiba, T., Dempsey, P. W., Ware, C. F., Loo, J. A., and Cheng, G. (2010). Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. Sci. Signal. 3, ra41.
110. Reiley, W. W., Jin, W., Lee, A. J., Wright, A., Wu, X., Tewalt, E. F., Leonard, T. O., Norbury, C. C., Fitzpatrick, L., Zhang, M., and Sun, S. C. (2007). Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204, 1475-1485.
111. Reiley, W. W., Zhang, M., Jin, W., Losiewicz, M., Donohue, K. B., Norbury, C. C., and Sun, S. C. (2006). Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 7, 411-417.
112. Rong, S. B., Hu, Y., Enyedy, I., Powis, G., Meuillet, E. J., Wu, X., Wang, R., Wang, S., and Kozikowski, A. P. (2001). Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J. Med. Chem. 44, 898-908.
113. Sasaki, Y., Calado, D. P., Derudder, E., Zhang, B., Shimizu, Y., Mackay, F., Nishikawa, S., Rajewsky, K., and Schmidt-Supprian, M. (2008). NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc. Natl. Acad. Sci. U.S.A. 105, 10883-10888.
114. Sato, S., Sanjo, H., Takeda, K., Ninomiya-Tsuji, J., Yamamoto, M., Kawai, T., Matsumoto, K., Takeuchi, O., and Akira, S. (2005). Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087-1095.
115. Sato, Y., Yoshikawa, A., Yamagata, A., Mimura, H., Yamashita, M., Ookata, K., Nureki, O., Iwai, K., Komada, M., and Fukai, S. (2008). Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains. Nature 455, 358-362.
116. Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O'Rourke, K., Bazan, F., Eastham-Anderson, J., Yue, P., Dornan, D., Huang, D. C., and Dixit, V. M. (2010). Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463, 103-107.
117. Shambharkar, P. B., Blonska, M., Pappu, B. P., Li, H., You, Y., Sakurai, H., Darnay, B. G., Hara, H., Penninger, J., and Lin, X. (2007). Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. EMBO J. 26, 1794-1805.
118. Shan, J., Zhao, W., and Gu, W. (2009). Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol. Cell 36, 469-476.
119. Shao, G., Lilli, D. R., Patterson-Fortin, J., Coleman, K. A., Morrissey, D. E., and Greenberg, R. A. (2009). The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc. Natl. Acad. Sci. U. S. A. 106, 3166-3171.
120. Shembade, N., Ma, A., and Harhaj, E. W. (2010). Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327, 1135-1139.
121. Shembade, N., Parvatiyar, K., Harhaj, N. S., and Harhaj, E. W. (2009). The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J. 28, 513-522.
122. Shim, J. H., Xiao, C., Paschal, A. E., Bailey, S. T., Rao, P., Hayden, M. S., Lee, K. Y., Bussey, C., Steckel, M., Tanaka, N., Yamada, G., Akira, S., Matsumoto, K., and Ghosh, S. (2005). TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19, 2668-2681.
123. Shoji, K., Oda, K., Nakagawa, S., Hosokawa, S., Nagae, G., Uehara, Y., Sone, K., Miyamoto, Y., Hiraike, H., Hiraike-Wada, O., Nei, T., Kawana, K., Kuramoto, H., Aburatani, H., Yano, T., and Taketani, Y. (2009). The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br. J. Cancer 101, 145-148.
124. Silverman, N., Zhou, R., Erlich, R. L., Hunter, M., Bernstein, E., Schneider, D., and Maniatis, T. (2003). Immune activation of NF-kappaB and JNK requires Drosophila TAK1. J. Biol. Chem. 278, 48928-48934.
125. Skaug, B., Chen, J., Du, F., He, J., Ma, A., and Chen, Z. J. (2011). Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 44, 559-571.
126. Skaug, B., Jiang, X., and Chen, Z. J. (2009). The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 78, 769-796.
127. Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C. H., and Landström, M. (2008). The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10, 1199-1207.
128. Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., and Evan, G. I. (2008). Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683.
129. Staal, S. P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 84, 5034-5037.
130. Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., and Robertson, G. P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
131. Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., Buckstein, R., Lam, W., Humphries, R. K., and Karsan, A. (2010). Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat. Med. 16, 49-58.
132. Suizu, F., Hiramuki, Y., Okumura, F., Matsuda, M., Okumura, A. J., Hirata, N., Narita, M., Kohno, T., Yokota, J., Bohgaki, M., Obuse, C., Hatakeyama, S., Obata, T., and Noguchi, M. (2009). The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev. Cell 17, 800-810.
133. Sun, L., Deng, L., Ea, C. K., Xia, Z. P., and Chen, Z. J. (2004). The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14, 289-301.
134. Sun, S. C. (2008). Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8, 501-511.
135. Sun, S. C. (2010). CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 17, 25-34.
136. Sun, S. C. (2011). Non-canonical NF-kappaB signaling pathway. Cell Res. 21, 71-85.
137. Takaesu, G., Surabhi, R. M., Park, K. J., Ninomiya-Tsuji, J., Matsumoto, K., and Gaynor, R. B. (2003). TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J. Mol. Biol. 326, 105-115.
138. Teitell, M. A. (2005). The TCL1 family of oncoproteins: co-activators of transformation. Nat. Rev. Cancer 5, 640-648.
139. Toker, A. (2009). TTC3 ubiquitination terminates Akt-ivation. Dev. Cell 17, 752-754.
140. Vallabhapurapu, S., Matsuzawa, A., Zhang, W., Tseng, P. H., Keats, J. J., Wang, H., Vignali, D. A., Bergsagel, P. L., and Karin, M. (2008). Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 9, 1364-1370.
141. Varfolomeev, E., Goncharov, T., Fedorova, A. V., Dynek, J. N., Zobel, K., Deshayes, K., Fairbrother, W. J., and Vucic, D. (2008). c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J. Biol. Chem. 283, 24295-24299.
142. Varnai, P., Bondeva, T., Tamás, P., Tóth, B., Buday, L., Hunyady, L., and Balla, T. (2005). Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners. J. Cell. Sci. 118(Pt 20), 4879-4888.
143. Vidal, S., Khush, R. S., Leulier, F., Tzou, P., Nakamura, M., and Lemaitre, B. (2001). Mutations in the Drosophila dTAK1 gene reveal a conserved function for MAPKKKs in the control of rel/NF-kappaB-dependent innate immune responses. Genes Dev. 15, 1900-1912.
144. Virdee, S., Ye, Y., Nguyen, D. P., Komander, D., and Chin, J. W. (2010). Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. Nat. Chem. Biol. 6, 750-757.
145. Wan, Y. Y., Chi, H., Xie, M., Schneider, M. D., and Flavell, R. A. (2006). The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 7, 851-858.
146. Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., and Chen, Z. J. (2001). TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351.
147. Weissman, A. M., Shabek, N., and Ciechanover, A. (2011). The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat. Rev. Mol. Cell Biol. 12, 605-620.
148. Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., Ma, A., Koonin, E. V., and Dixit, V. M. (2004). De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694-699.
149. Williams, S. A., Maecker, H. L., French, D. M., Liu, J., Gregg, A., Silverstein, L. B., Cao, T. C., Carano, R. A., and Dixit, V. M. (2011). USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 146, 918-930.
150. Wiltshire, T. D., Lovejoy, C. A., Wang, T., Xia, F., O'Connor, M. J., and Cortez, D. (2010). Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J. Biol. Chem. 285, 14565-14571.
151. Winborn, B. J., Travis, S. M., Todi, S. V., Scaglione, K. M., Xu, P., Williams, A. J., Cohen, R. E., Peng, J., and Paulson, H. L. (2008). The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J. Biol. Chem. 283, 26436-26443.
152. Wu, H., Tschopp, J., and Lin, S. C. (2007). Smac mimetics and TNFalpha: a dangerous liaison? Cell 131, 655-658.
153. Wu, Z. H., Wong, E. T., Shi, Y., Niu, J., Chen, Z., Miyamoto, S., and Tergaonkar, V. (2010). ATM-and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 40, 75-86.
154. Xia, Z. P., Sun, L., Chen, X., Pineda, G., Jiang, X., Adhikari, A., Zeng, W., and Chen, Z. J. (2009). Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461, 114-119.
155. Xiang, T., Ohashi, A., Huang, Y., Pandita, T. K., Ludwig, T., Powell, S. N., and Yang, Q. (2008). Negative regulation of AKT activation by BRCA1. Cancer Res. 68, 10040-10044.
156. Xu, K., Shimelis, H., Linn, D. E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., Kong, X., Melamed, J., Fang, S., Xiao, Z., Veenstra, T. D., and Qiu, Y. (2009). Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15, 270-282.
157. Yamashita, M., Fatyol, K., Jin, C., Wang, X., Liu, Z., and Zhang, Y. E. (2008). TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 31, 918-924.
158. Yamazaki, K., Gohda, J., Kanayama, A., Miyamoto, Y., Sakurai, H., Yamamoto, M., Akira, S., Hayashi, H., Su, B., and Inoue, J. (2009). Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling. Sci. Signal. 2, ra66.
159. Yang, W. L., Wang, J., Chan, C. H., Lee, S. W., Campos, A. D., Lamothe, B., Hur, L., Grabiner, B. C., Lin, X., Darnay, B. G., and Lin, H. K. (2009). The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134-1138.
160. Yang, W. L., Wu, C. Y., Wu, J., and Lin, H. K. (2010a). Regulation of Akt signaling activation by ubiquitination. Cell Cycle 9, 487-497.
161. Yang, W. L., Zhang, X., and Lin, H. K. (2010b). Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 29, 4493-4503.
162. Yeh, W. C., Shahinian, A., Speiser, D., Kraunus, J., Billia, F., Wakeham, A., de la Pompa, J. L., Ferrick, D., Hum, B., Iscove, N., Ohashi, P., Rothe, M., Goeddel, D. V., and Mak, T. W. (1997). Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7, 715-725.
163. Yu, Q., Geng, Y., and Sicinski, P. (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021.
164. Yuan, J., Luo, K., Zhang, L., Cheville, J. C., and Lou, Z. (2010). USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396.
165. Zarnegar, B., Yamazaki, S., He, J. Q., and Cheng, G. (2008a). Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc. Natl. Acad. Sci. U.S.A. 105, 3503-3508.
166. Zarnegar, B. J., Wang, Y., Mahoney, D. J., Dempsey, P. W., Cheung, H. H., He, J., Shiba, T., Yang, X., Yeh, W. C., Mak, T. W., Korneluk, R. G., and Cheng, G. (2008b). Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9, 1371-1378.
167. Zhang, J., Stirling, B., Temmerman, S. T., Ma, C. A., Fuss, I. J., Derry, J. M., and Jain, A. (2006). Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 116, 3042-3049.
168. Zhang, L., Blackwell, K., Thomas, G. S., Sun, S., Yeh, W. C., and Habelhah, H. (2009). TRAF2 suppresses basal IKK activity in resting cells and TNFalpha can activate IKK in TRAF2 and TRAF5 double knockout cells. J. Mol. Biol. 389, 495-510.
169. Zhang, L., Ding, X., Cui, J., Xu, H., Chen, J., Gong, Y. N., Hu, L., Zhou, Y., Ge, J., Lu, Q., Liu, L., Chen, S., and Shao, F. (2012). Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB activation. Nature 481, 204-208.
170. Zhong, Q., Gao, W., Du, F., and Wang, X. (2005). Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095.
171. Zilberman, D. E., Cohen, Y., Amariglio, N., Fridman, E., Ramon, J., and Rechavi, G. (2009). AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma. Cancer Genet. Cytogenet. 191, 34-37.